Global Plasma-derived Therapies Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Publication ID:

GIR102416494

Publication Date:

October 29, 2024

Pages:

101

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

IT & eHealth [2]

Pharma & Healthcare [3]

Description:

According to our latest research, the global Plasma-derived Therapies market size will reach USD million in 2030, growing at a CAGR of % over the analysis period.
Plasma-derived therapeutics start from human blood plasma instead of the chemical or synthetic materials from which most pharmaceuticals are made.
The Plasma-derived Therapies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Market segmentation
Plasma-derived Therapies market is split by Type and by Application. For the period 2024-2030, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Albumin
Immunoglobulin
Factor VIII
Others
Market segment by Application, can be divided into
Hemophilia
Primary Immunodeficiencies (PIDs)
Idiopathic Thrombocytopenic Purpura (ITP)
COVID-19
Others
Market segment by players, this report covers
CSL Behring LLC
Shire
Bayer
Kedrion
Takeda
Biotest
Octaparma
Bio Products Laboratory (BPL)
LFB
Grifols
Market segment by regions, regional analysis covers
North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia-Pacific)
South America
Middle East & Africa
The content of the study subjects, includes a total of 8 chapters:
Chapter 1, to describe Plasma-derived Therapies product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Plasma-derived Therapies, with recent developments and future plans
Chapter 3, the Plasma-derived Therapies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4, to break the market size data at the region level, with key companies in the key region and Plasma-derived Therapies market forecast, by regions, with revenue, from 2024 to 2030.
Chapter 5 and 6, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2024 to 2030.
Chapter 7 and 8, to describe Plasma-derived Therapies research findings and conclusion, appendix and data source.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Product Overview and Scope of Plasma-derived Therapies
1.2 Classification of Plasma-derived Therapies by Type
1.2.1 Overview: Global Plasma-derived Therapies Market Size by Type: 2024 Versus 2030
1.2.2 Global Plasma-derived Therapies Revenue Market Share by Type in 2030
1.2.3 Albumin
1.2.4 Immunoglobulin
1.2.5 Factor VIII
1.2.6 Others
1.3 Global Plasma-derived Therapies Market by Application
1.3.1 Overview: Global Plasma-derived Therapies Market Size by Application: 2024 Versus 2030
1.3.2 Hemophilia
1.3.3 Primary Immunodeficiencies (PIDs)
1.3.4 Idiopathic Thrombocytopenic Purpura (ITP)
1.3.5 COVID-19
1.3.6 Others
1.4 Global Plasma-derived Therapies Market Size & Forecast
1.5 Market Drivers, Restraints and Trends
1.5.1 Plasma-derived Therapies Market Drivers
1.5.2 Plasma-derived Therapies Market Restraints
1.5.3 Plasma-derived Therapies Trends Analysis
2 Company Profiles
2.1 CSL Behring LLC
2.1.1 CSL Behring LLC Details
2.1.2 CSL Behring LLC Major Business
2.1.3 CSL Behring LLC Plasma-derived Therapies Product and Solutions
2.1.4 CSL Behring LLC Recent Developments and Future Plans
2.2 Shire
2.2.1 Shire Details
2.2.2 Shire Major Business
2.2.3 Shire Plasma-derived Therapies Product and Solutions
2.2.4 Shire Recent Developments and Future Plans
2.3 Bayer
2.3.1 Bayer Details
2.3.2 Bayer Major Business
2.3.3 Bayer Plasma-derived Therapies Product and Solutions
2.3.4 Bayer Recent Developments and Future Plans
2.4 Kedrion
2.4.1 Kedrion Details
2.4.2 Kedrion Major Business
2.4.3 Kedrion Plasma-derived Therapies Product and Solutions
2.4.4 Kedrion Recent Developments and Future Plans
2.5 Takeda
2.5.1 Takeda Details
2.5.2 Takeda Major Business
2.5.3 Takeda Plasma-derived Therapies Product and Solutions
2.5.4 Takeda Recent Developments and Future Plans
2.6 Biotest
2.6.1 Biotest Details
2.6.2 Biotest Major Business
2.6.3 Biotest Plasma-derived Therapies Product and Solutions
2.6.4 Biotest Recent Developments and Future Plans
2.7 Octaparma
2.7.1 Octaparma Details
2.7.2 Octaparma Major Business
2.7.3 Octaparma Plasma-derived Therapies Product and Solutions
2.7.4 Octaparma Recent Developments and Future Plans
2.8 Bio Products Laboratory (BPL)
2.8.1 Bio Products Laboratory (BPL) Details
2.8.2 Bio Products Laboratory (BPL) Major Business
2.8.3 Bio Products Laboratory (BPL) Plasma-derived Therapies Product and Solutions
2.8.4 Bio Products Laboratory (BPL) Recent Developments and Future Plans
2.9 LFB
2.9.1 LFB Details
2.9.2 LFB Major Business
2.9.3 LFB Plasma-derived Therapies Product and Solutions
2.9.4 LFB Recent Developments and Future Plans
2.10 Grifols
2.10.1 Grifols Details
2.10.2 Grifols Major Business
2.10.3 Grifols Plasma-derived Therapies Product and Solutions
2.10.4 Grifols Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Plasma-derived Therapies Revenue and Share by Players (2024 & 2030)
3.2 Plasma-derived Therapies Players Head Office, Products and Services Provided
3.3 Plasma-derived Therapies Mergers & Acquisitions
3.4 Plasma-derived Therapies New Entrants and Expansion Plans
4 Global Plasma-derived Therapies Forecast by Region
4.1 Global Plasma-derived Therapies Market Size by Region: 2024 VS 2030
4.2 Global Plasma-derived Therapies Market Size by Region, (2024-2030)
4.3 North America
4.3.1 Key Companies of Plasma-derived Therapies in North America
4.3.2 Current Situation and Forecast of Plasma-derived Therapies in North America
4.3.3 North America Plasma-derived Therapies Market Size and Prospect (2024-2030)
4.4 Europe
4.4.1 Key Companies of Plasma-derived Therapies in Europe
4.4.2 Current Situation and Forecast of Plasma-derived Therapies in Europe
4.4.3 Europe Plasma-derived Therapies Market Size and Prospect (2024-2030)
4.5 Asia-Pacific
4.5.1 Key Companies of Plasma-derived Therapies in Asia-Pacific
4.5.2 Current Situation and Forecast of Plasma-derived Therapies in Asia-Pacific
4.5.3 Asia-Pacific Plasma-derived Therapies Market Size and Prospect (2024-2030)
4.5.4 China
4.5.5 Japan
4.5.6 South Korea
4.6 South America
4.6.1 Key Companies of Plasma-derived Therapies in South America
4.6.2 Current Situation and Forecast of Plasma-derived Therapies in South America
4.6.3 South America Plasma-derived Therapies Market Size and Prospect (2024-2030)
4.7 Middle East & Africa
4.7.1 Key Companies of Plasma-derived Therapies in Middle East & Africa
4.7.2 Current Situation and Forecast of Plasma-derived Therapies in Middle East & Africa
4.7.3 Middle East & Africa Plasma-derived Therapies Market Size and Prospect (2024-2030)
5 Market Size Segment by Type
5.1 Global Plasma-derived Therapies Market Forecast by Type (2024-2030)
5.2 Global Plasma-derived Therapies Market Share Forecast by Type (2024-2030)
6 Market Size Segment by Application
6.1 Global Plasma-derived Therapies Market Forecast by Application (2024-2030)
6.2 Global Plasma-derived Therapies Market Share Forecast by Application (2024-2030)
7 Research Findings and Conclusion
8 Appendix
8.1 Methodology
8.2 Research Process and Data Source
8.3 Disclaimer

Companies Mentioned:

CSL Behring LLC
Shire
Bayer
Kedrion
Takeda
Biotest
Octaparma
Bio Products Laboratory (BPL)
LFB
Grifols

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂